# IM Cannabis Corp.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/IM Cannabis Corp.).

## Overview

IM Cannabis Corp. is a medical cannabis company with operations in Israel and Germany. The company imports, distributes, and retails medical cannabis products through pharmacies, trade houses, and online platforms, and it also operates branded cannabis portfolios in Europe.

## Products & services

• Medical cannabis flowers
• Full-spectrum cannabis extracts
• Cannabis import and distribution
• Medical cannabis retail pharmacies
• Online patient ordering platforms
• Branded cannabis strains and product portfolios

- **Medical cannabis flowers** (45%) — Dried flower products sold to medical patients through pharmacies and distributors.
- **Cannabis extracts** (20%) — Full-spectrum extracts and related medical cannabis formulations.
- **Import and wholesale distribution** (20%) — Imported cannabis supplied to pharmacies and trade houses in core markets.
- **Retail pharmacies and online channels** (10%) — Patient-facing dispensing and digital ordering platforms in Israel.
- **Branded portfolio and other products** (5%) — IMC-branded, mid-market, value, and premium cannabis products.

- Medical cannabis flowers
- Full-spectrum cannabis extracts
- Cannabis import and distribution
- Medical cannabis retail pharmacies
- Online patient ordering platforms
- Branded cannabis strains and product portfolios

## Customers

IM Cannabis primarily serves medical cannabis patients, with products reaching them through pharmacies, trade houses, and company-operated retail channels. In Germany, the company sells through pharmacies serving medical patients, while in Israel it supplies patients via licensed pharmacies and its own retail and online platforms. The buyer set is therefore mostly medical end users, with pharmacies and distributors acting as the key channel customers.

- **Medical patients in Israel** (primary) — Buy imported and locally supplied medical cannabis through licensed pharmacies and IMC retail channels for prescribed treatment.
- **Medical patients in Germany** (primary) — Receive cannabis products through pharmacies supplied by IMC's German distribution business.
- **Pharmacies and dispensaries** (primary) — Purchase cannabis products for prescription fulfillment and patient dispensing.
- **Wholesale and trade house partners** (secondary) — Buy product inventory and distribution services that link supply to the patient channel.
- **Online patient channel users** (secondary) — Order medical cannabis through IMC-operated digital platforms in Israel for convenience and control.

- Medical cannabis patients in Israel and Germany
- Pharmacies that dispense prescriptions to patients
- Trade houses and wholesale channel partners
- Patients using company retail pharmacies in Israel
- Patients ordering through online medical platforms

## Geography

IM Cannabis is centered on Israel and Germany, which together represent the company’s core operating footprint and revenue base. The business also uses Canadian sourcing and cultivation relationships to support supply into its patient markets, but commercial activity is concentrated in Europe and Israel. Geography matters because each market has distinct medical-cannabis regulation, licensing, and distribution requirements that shape how the company sells and operates.

- **Israel** (50%) — Estimated core operating market based on disclosures
- **Germany** (50%) — Estimated core operating market based on disclosures

- Core operations are in Israel and Germany
- Canadian sourcing supports supply into core markets
- Israel includes pharmacies, trade houses, and online channels
- Germany relies on pharmacy distribution and EU-GMP operations
- Local regulation and licensing shape market access

## Strategy

IM Cannabis is focused on building a branded medical-cannabis platform across Israel and Germany, using distribution, retail, and product branding as its main commercial levers. The company’s strategy also emphasizes supply reliability, portfolio expansion across price tiers, and leveraging patient and product data to support market positioning. It continues to evaluate opportunities to extend into additional technology-driven sectors, but its present operating model remains centered on medical cannabis.

- **Expand branded product portfolio** (short-term) — A broader price ladder helps reach more patients and improve shelf presence across pharmacies.
- **Secure and diversify supply** (medium-term) — Medical cannabis demand depends on consistent product availability and regulatory-compliant sourcing.
- **Deepen pharmacy channel access** (short-term) — Pharmacies are the main route to medical patients in both core markets.
- **Leverage patient data and brand reputation** (medium-term) — Historical usage data and credibility can support product development and repeat demand.

- Strengthen branded medical cannabis positioning
- Expand across premium, mid-market, and value tiers
- Maintain reliable supply into pharmacy channels
- Use patient insights and proprietary data
- Evaluate adjacent technology-driven opportunities

## Risks

IM Cannabis is exposed to regulatory, licensing, and execution risks because its business depends on medical-cannabis approvals, import permissions, and pharmacy distribution in tightly controlled markets. It also faces supply-chain and quality-control risk from cross-border sourcing, plus valuation and impairment risk tied to goodwill and other judgmental balance-sheet items. Industry competition, pricing pressure, and changing patient demand can affect sell-through across both Israel and Germany.

- **Regulatory and licensing dependency** [high] — The company operates only through medical-cannabis permits, import rights, and pharmacy distribution approvals.
- **Supply-chain and sourcing disruption** [high] — The model relies on Canadian suppliers, imports, and third-party cultivation to maintain product availability.
- **Goodwill impairment** [high] — The group tests goodwill against estimated future cash flows from Israel, Canada, and Germany cash-generating units.
- **Competitive pricing pressure** [medium] — Medical cannabis markets feature branded and generic substitutes, which can compress demand for higher-priced products.

- Medical cannabis regulation and licensing can change market access
- Cross-border sourcing creates supply and quality-control risk
- Pharmacy and distributor relationships are critical to sales
- Goodwill and asset values depend on future cash flow estimates
- Competition and pricing pressure can affect branded product uptake

## Accounting

IM Cannabis uses judgment-heavy accounting in areas that can materially affect reported results, especially goodwill impairment testing and fair-value measurements for unquoted financial assets. The company also must estimate contingent liabilities, legal claims, and other provisions, while revenue timing depends on product shipment and pharmacy/channel fulfillment in regulated markets. Because it reports in multiple currencies and operates across jurisdictions, foreign exchange effects and asset valuations can also move reported numbers.

- **Goodwill impairment** — Can create large non-cash charges if forecasts weaken
- **Fair value of unquoted financial assets** — Changes estimates and reported asset values
- **Legal claims and contingent liabilities** — Can affect expenses and liabilities
- **Foreign exchange translation** — Can move reported earnings and equity

- Goodwill impairment depends on future cash flow assumptions
- Fair value of unquoted assets uses discounted cash flow estimates
- Legal claims and provisions require management judgment
- Multi-currency operations create foreign exchange effects
- Channel-based sales can affect revenue timing and comparability

---

*Last updated: 2026-09-28T12:04:01.914601+00:00*